Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Amsterdam Molecular Therapeutics grosses €55.7mm in IPO

Executive Summary

Gene drug developer Amsterdam Molecular Therapeutics BV has grossed €55.7mm ($72.4mm) in its initial public offering on Euronext Amsterdam's Eurolist. It sold 5.5mm new ordinary shares (including a partial exercise of the overallotment) at €10 each. Earlier this month the company planned to offer the shares at €8-10 apiece.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies